H.I.G. BioVentures leads Series C round for ForSight VISION5

ForSight VISION5 has closed $15 million in Series C financing. H.I.G. BioVentures led the round with participation from previous backers Morgenthaler Ventures, Versant Ventures, Technology Partners and Delphi Ventures. Concurrent with the funding, Aaron Davidson of H.I.G. BioVentures has been added to ForSight VISION5′s board of directors. Based in Menlo Park, Calif., ForSight VISION5 focuses on developing products that replace eye drops.

Sequent Medical rakes in $20 mln

Sequent Medical said Tuesday that it has received $20 million in Series D financing. Previous backer Delphi Ventures led the round with participation from Domain Associates, US Venture Partners and Versant Ventures. Headquartered in Aliso Viejo, Calif., Sequent Medical is a medical-device company focused on catheter-based neurovascular technologies.

RuiYi nets $15 mln Series B funds

Sino-American biotech company RuiYi said Thursday that it has raised $15 million in Series B financing. The investors were 5AM Ventures, Versant Ventures, Apposite Capital, SR One, the independent corporate healthcare venture capital fund of GlaxoSmithKline, Merck Serono Ventures, the strategic corporate venture fund of Merck Serono, and Aravis SA.

VC-backed Achaogen debuts IPO

Achaogen has launched its IPO after pricing its 6 million shares at $12 per share. The stock began trading Wednesday on the NASDAQ under the ticker symbol “AKAO.” Credit Suisse Securities and Cowen and Company are the lead underwriters. Based in South San Francisco, Achaogen is a biopharmaceutical company focused on developing antibiotics to treat bacterial infections. Its backers include 5AM Ventures, ARCH Venture Partners, Venrock, Versant Ventures, Frazier Healthcare Ventures, Domain Associates and Alta Partners.

Versant to raise $250M fifth fund

Versant Ventures has filed with the Securities and Exchange Commission to raise a $250 million fifth fund. The fund’s first close has yet to occur. Versant Venture Capital V will be run by managing directors Robin Praeger, Bradley Bolzon, Samuel Colella, Ross Jaffe, William Link, Kirk Nielsen and Charles Warden, according to the filing dated Oct. 18.

Novira Therapeutics Completes Series A Financing

Novira Therapeutics has completed a Series A financing after securing $7.5 million from new investor Versant Ventures. This brings the total raised from all investors in the round to $25 million. Versant joins 5AM Ventures and Canaan Partners, which led the first closing of the Series A in August 2012.

Teleflex Acquires Hotspur Technologies

Teleflex, a provider of medical devices for critical care and surgery, has acquired Hotspur Technologies. Hotspur Technologies, based in Mountain View, CA, is a developer of innovative, catheter-based technologies aimed at restoring blood flow for patients with obstructed vessels. Prior to the acquisition by Teleflex, Hotspur was privately held. Investors included ONSET Ventures, Finistere Ventures, […]

Life Sci VCs Versant Plot Fund V

Life sciences and biotech VCs don’t have it easy–and Versant Ventures, with a lengthy track record, is out to buck the trend and raise a big new fund, peHUB has learned.

Benvenue Medical Appoints Two to Board

Benvenue Medical, a developer of minimally invasive solutions for spine repair, has appointed two new members to its board of directors. Thomas M. Prescott, president and CEO of Align Technology and Thomas C. Wilder, president and CEO of Sequent Medical are both experienced in bringing medical technologies to the global marketplace. Investors in Benvenue Medical […]

PEHUB Community

Join the 12494 members of peHUB to make connections, share your opinion, and follow your favorite authors.

Join the Community

Psst! Got any hot tips?

  • This field is for validation purposes and should be left unchanged.

Look Who’s Tweeting

Reuters VC and PE feed

RSS Feed Widget

Groups